



Original Article

In vivo assessment of endothelial function in small animals using an infrared pulse detector

Cyuan-Cin Liu^a, Wei-Min Liu^b, Hsien-Tsai Wu^a, Chien-Hsing Wang^c, An-Bang Liu^{d*}

^aDepartment of Electrical Engineering, National Dong Hwa University, Hualien, Taiwan,

^bDepartment of Computer Science and Information Engineering, National Chung Cheng University, Chiayi, Taiwan,

^cDepartment of Surgery, Buddhist Tzu Chi General Hospital, Hualien, Taiwan,

^dDepartment of Neurology, Buddhist Tzu Chi General Hospital and Tzu Chi University, Hualien, Taiwan

Received : 23-Dec-2017
Revised : 11-Mar-2018
Accepted : 20-Mar-2018

ABSTRACT

Objective: Endothelial dysfunction is the earliest change in atherosclerosis. Flow-mediated dilatation (FMD) is used to assess endothelial function in humans. However, this assessment is not easy in small animals. This study demonstrated the reliability and reproducibility of a proposed instrument for *in vivo* assessment of FMD in a rodent model using infrared pulse sensors. **Materials and Methods:** We used 24 adult male Wistar Kyoto rats randomly divided into three groups. FMD was measured under continuous infusion of normal saline followed by intra-arterial infusion of acetylcholine (Ach; $n = 8$), sodium nitroprusside (SNP; $n = 8$), or N^ω-nitro-L-arginine methyl ester (L-NAME; $n = 8$). **Results:** The dilatation indices (DIs) of all three groups were similar before application of the vasoactive agents (1.82 ± 0.46 , 1.81 ± 0.44 , and 1.93 ± 0.40 , $P = 0.877$, by one-way analysis of variance). The DI was significantly increased during infusion of Ach (2.97 ± 1.03 vs. 1.82 ± 0.46 , $P = 0.015$), unchanged during infusion of SNP (1.81 ± 0.44 vs. 1.98 ± 0.40 , $P = 0.574$), and attenuated during infusion of L-NAME (1.91 ± 0.40 vs. 1.42 ± 0.35 ; $P = 0.028$). **Conclusion:** The results of this study correlated well with those of human studies, suggesting that this method can be used for *in vivo* evaluation of endothelial function in small animals.

KEYWORDS: Endothelial function, Flow-mediated dilatation, Nitric oxide

INTRODUCTION

The vascular endothelium is a single layer of cells lining the inner surface of vasculature, which also plays an important role in cardiovascular homeostasis. In addition to maintaining vascular tone, the endothelial cell has anti-thrombotic, fibrinolytic, and anti-inflammatory effects. It also inhibits proliferation of underlying smooth muscle cells [1]. *Ex vivo* assessment of endothelial function has been used since early 1980 by measuring the constriction and relaxation of isolated thoracic aortic ring with the application of acetylcholine (Ach) [2]. Initially, endothelial function was assessed invasively by measuring vasomotor changes on endothelium during local administration of drugs, such as Ach, substance P, or bradykinin [3,4].

Several noninvasive methods were developed over the past three decades. One commonly used measurement, flow-mediated dilatation (FMD), also called reactive hyperemia, assesses increases in the regional blood flow or vessel diameter after transient occlusion of upstream or downstream arteries. The increase in blood flow and also shear stress on the wall after reperfusion stimulate production and release of endothelium-derived nitric oxide, thereby causing vasodilatation [5].

FMD is a simple and reliable method to assess endothelial function and nitric oxide bioavailability, with the use of ultrasonography or tonometry to record changes in vessel diameter or blood flow [6]. From clinical observations, endothelial dysfunction occurs in the early stage of atherosclerosis and attenuation of FMD is associated with many atherosclerosis-related diseases [7,8]. Since endothelial dysfunction predicts poor clinical outcomes or occurrence of atherosclerosis-related diseases [9-14], closely monitoring endothelial function may provide an early warning and an opportunity for early intervention.

A growing number of therapeutic interventions (e.g., exercise, weight reduction, smoking cessation, and treatment with statins and angiotensin-converting enzyme inhibitors) are known to decrease atherosclerosis-related risks and also improve endothelial function in human subjects [15-17]. However, it is not easy to assess endothelial function in small animals, which is an important issue for drug

*Address for correspondence:

Dr. An-Bang Liu,
Department of Neurology, Buddhist Tzu Chi General Hospital, 707,
Section 3, Chung-Yang Road, Hualien, Taiwan.
E-mail: liuabpaper@yahoo.com.tw

Access this article online

Quick Response Code:



Website: www.tcmjmed.com

DOI: 10.4103/tcmj.tcmj_94_18

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com

How to cite this article: Liu CC, Liu WM, Wu HT, Wang CH, Liu AB. *In vivo* assessment of endothelial function in small animals using an infrared pulse detector. Tzu Chi Med J 2019;31(4):217-21.

development and exploration of disease pathophysiology. In rodents, most reported methods are invasive and require sacrificing the animals at each time point during the study [18-20]. The only method available for repeated assessment of endothelial function in living rats uses a 35-MHz high-resolution ultrasound imaging system to measure changes in the diameter of the femoral artery during FMD [21]. It is time-consuming and must be performed by experienced technicians using expensive equipment. This system has been used in only a few studies [22]. Here, we propose an instrument of novel design that uses infrared photoplethysmographic (PPG) sensors to provide easy and reliable measurements of endothelial function (i.e., FMD) in rats without the necessity to sacrifice animals at each time point and furthermore allows repeated measurements over a long period. We also proved that changes in volume flow are mostly mediated by endothelium-releasing nitric oxide.

MATERIALS AND METHODS

Animals

All animal procedures were approved by the Institutional Animal Care and Use Committee of Tzu Chi General Hospital (IACUC Approval No. 98-43-1). Male Wistar Kyoto (WKY) rats (6–9 weeks old) were purchased from the National Laboratory Animal Breeding and Research Center, Taipei, Taiwan. These animals were bred in a specific pathogen-free environment at 25°C with 12:12 h light-dark cycles and allowed free access to food and water in the Animal Center of Tzu Chi University. The animals were anesthetized with an intraperitoneal injection of sodium pentobarbital (50 mg/kg) and placed in a supine position on a heating pad maintained at 37°C [23].

Measurement of flow-mediated dilatation

An infrared sensor was fixed on the footpad of the right hind limb [Figure 1]. The common iliac artery and its branch, the internal iliac artery, were isolated carefully under a dissecting microscope [24] [Figure 2]. A P10 polyethylene tube was inserted into this artery and attached to a 3-mL syringe.




Figure 1: Setup of the experimental platform. The deep femoral artery was explored at the inguinal area (a) and then connected to an infusion machine with a P10 polyethylene tube (b). An infrared sensor (c) was attached to the footpad of the hind limb and then connected to a signal processing module containing a USB-6009 DAQ card for filtration and digitalization

The syringe was fixed to an infusion pump (NE-1600 New Era Pump Systems Inc., NY, USA). An infrared sensor was attached to the footpad of the right hind limb [Figure 1]. The volume pulses were recorded by PPG, transmitted to a signal processing module containing a USB-6009 DAQ (National Instruments, Austin, TX, USA), and converted to digital signals as previously described [23]. The signals were filtered with a band-pass of 0.3–3 Hz, amplified, and then processed to a personal computer for storage and analysis.

Experimental protocol for flow-mediated dilatation

It took about 30 min for cannulation and acclimatization. After cannulation, the animals received a continuous intra-arterial infusion of normal saline at a rate of 10 $\mu\text{L}/\text{min}$. After pulse stabilization (about 5 min), the baseline volume pulses were recorded for 1 min. Then, the external iliac artery was occluded using a hemostatic clip at the proximal site for 5 min [Figure 3a]. The dilatation index (DI) was calculated as the ratio of the mean pulse amplitude recorded during a 1-min period 1 min after release of the clip to the 1-min mean pulse amplitude before occlusion of the artery [Figure 3b] [25].

After recording the baseline DIs, the animals received an intra-arterial infusion of Ach (Sigma-Aldrich, St. Louis, MO, USA), sodium nitroprusside (SNP, Mayne Pharma Pty Ltd, Melbourne, Victoria, Australia), or a nitric oxide synthase inhibitor, N^{ω} -nitro- L -arginine methyl ester (L -NAME, Sigma-Aldrich, St. Louis, MO, USA). The infusion rate was 10 $\mu\text{L}/\text{min}$ at a dosage of 1 $\mu\text{g}/\text{min}$ for Ach, 1 $\mu\text{g}/\text{min}$ for SNP, and 1.7 $\mu\text{g}/\text{min}$ for L -NAME [26]. The same procedures were repeated to check DIs during infusion of each drug.

To test reliability of the measurements, two consecutive measurements of the DI were performed in the right and left hind limbs of five rats at an interval of 1 week. The agreement of the measurement was demonstrated by Bland–Altman plotting.

Statistical analysis

All data are expressed as mean \pm standard deviation. To check the reliability of the measurement, we performed linear regression between the first and second measurements. We used Student's *t*-test to check the difference in the DIs between the left and right side. The effects of drugs on FMD




Figure 2: Anatomic relationship of the arteries used for the hyperemic test at the dissection site. The internal iliac artery was catheterized with a P10 polyethylene tube and connected to an infusion pump for continuous infusion of pharmacological agents. For the hyperemic test, a hemostatic clip was placed at a proximal site on the common iliac artery for transient occlusion of blood flow




Figure 3: (a) The experimental protocol. About 30 min were required for cannulation and acclimatization. Then the animals received a continuous intra-arterial infusion of normal saline until stabilization of the pulse (about 5 min). The baseline pulse amplitude was recorded for 1 min (gray bar), and the common iliac artery was occluded by a hemostatic clip for 5 min (black bar). One minute after releasing the clip, the pulse amplitude was recorded for 1 min (gray bar), and the normal saline infusion was changed to acetylcholine, sodium nitroprusside, or N^o-nitro-L-arginine methyl ester. (b) The dilatation index was defined as the mean 1-min pulse amplitude (period b) 1 min after release of the clip divided by the mean 1-min pulse amplitude (period a) 1 min before occlusion of the left femoral artery

were assessed by comparing the FMD before and during infusion of the agents, and changes in FMD were analyzed with the nonparametric Mann–Whitney U-test. The homogeneity of baseline DIs was examined by one-way analysis of variance (ANOVA). All analyses were performed using SPSS (version 10.0, SPSS, Inc., Chicago, IL, USA). Statistical significance was accepted at $P < 0.05$.

RESULTS

Reproducibility of measurements

Two consecutive measurements of FMD were carried out on both sides of five rats, and therefore, 10 DIs were calculated the first time. One week later, FMDs were measured again. Ten more measurements were recorded in the 2nd week. There was very good agreement between the first and second measurements as assessed by Bland–Altman plotting [Figure 4]. There was no significant difference in measurements between sides (2.03 ± 0.69 vs. 1.83 ± 0.56 ; $P = 0.94$).

Effects of drugs on reactive hyperemic vasodilatation

Twenty-four WKY rats were divided into three groups of eight. DIs did not differ before infusion of the drugs ($P = 0.877$, by one-way ANOVA). DIs were increased from 1.82 ± 0.46 (at baseline) to 2.97 ± 1.03 ($P = 0.015$) during infusion of Ach, were unchanged (1.81 ± 0.44 vs. 1.98 ± 0.40 ; $P = 0.574$) after infusion of SNP, and were decreased (1.91 ± 0.40 vs. 1.42 ± 0.35 ; $P = 0.028$) after infusion of L-NAME. Although the baseline DI was higher in animals infused with L-NAME than in animals infused with Ach or SNP, the difference was not statistically significant by one-way ANOVA [Table 1 and Figure 5].

DISCUSSION

PPG is a simple optical technique that has been used to detect changes in microcirculatory perfusion in many tissues,




Figure 4: Reproducibility of the measurements was demonstrated by Bland–Altman plotting between the first and second assessments of both hind limbs of five animals at an interval of 1 week

Table 1: The effects of drugs on flow-mediated dilatation

Drug	DI at baseline	DI during infusion of drug	P
Acetylcholine (n=8)	1.82±0.46	2.97±1.03	0.015 [§]
Sodium nitroprusside (n=8)	1.81±0.44	1.98±0.40	0.574 [§]
L-NAME (n=8)	1.91±0.40	1.42±0.35	0.028 [§]
P	0.877*		

The DI of the animals before and during intra-arterial infusion of vasoactive agents. Values are presented as mean±SD. *There was no individual difference in DI before infusion of these drugs by one-way ANOVA. [§]Because of individual differences in response to vasoactive agents, the changes during and before infusion of drugs were evaluated by the nonparametric Mann–Whitney U-test. Statistical significance was accepted at $P < 0.05$. SD: Standard deviation, DI: Dilatation index, ANOVA: Analysis of variance

including the fingertips and earlobes. With the advantages of low cost, simple manipulation, and portability, PPG instruments with red or infrared sensors have been used to measure oxygen saturation, blood pressure, cardiac output, and autonomic function [27]. We have used a dual-channel PPG to measure the pulse-wave velocity in humans. These acquisitions and measurements of PPG have been shown to be reliable and reproducible [28,29].

In this study, we used a modified instrument to measure endothelial function in anesthetized adult WKY rats using infrared PPG to detect blood flow volume changes in the footpad. There are several definitions of DI, using either the ratio of the peak increase of blood flow after a hyperemic test to the baseline blood flow or the average of the pulse amplitude in a time interval to the mean amplitude at baseline [25,30]. In human study, DIs recorded during the 90–120-s postdeflation period had the strongest correlation with cardiovascular risk factors [31]. However, there is no established definition of DI for rats. The only study in which the DI in rats was measured with ultrasonography used the ratio of the maximal diameter to the baseline diameter after the hyperemic test to the baseline diameter [21]. We followed the protocol published by Nohria *et al.* to estimate the DI and used the ratio of the average amplitude of the pulse wave volume over a 1-min period




Figure 5: The effects of infusion of different vasoactive agents on the dilatation index ($n = 8$ in each group). Acetylcholine enhanced dilatation indices significantly ($P = 0.015$), N^o-nitro-L-arginine methyl ester attenuated dilatation indices ($P = 0.028$) and sodium nitroprusside did not have a significant effect on the FMD ($P = 0.574$)

starting 1 min after release of the hemostatic clip divided by the average of the pulse amplitude during a 1-min interval before occlusion of the artery [32]. Many factors affect the reproducibility of PPG, such as environmental temperature, proper sensor attachment, motion artifacts, and the subject's posture, breathing, and wakefulness [27]. In this study, we showed that excellent reproducibility could be achieved under general anesthesia and controlled room temperature conditions. Moreover, this instrument can be used for long-term and dynamic *in vivo* studies of endothelial function in small animals.

FMD is mainly mediated by the release of endothelial nitric oxide. In this study, we used three vasoactive agents to confirm that the volume pulse signal changes that we recorded by infrared sensors were also mediated by nitric oxide. Figure 5 shows their effects on the DI. The endothelium-dependent vasodilator Ach increased DI significantly. In contrast, intra-arterial infusion of L-NAME, a nitric oxide synthase inhibitor, attenuated flow-mediated dilatation. Another vasodilator, SNP, acting on vascular smooth muscle cells directly, did not affect the DI. These findings proved that the FMD data obtained by measurement with infrared PPG were similar to those obtained using other devices such as tonometry or high-resolution ultrasound in humans and rats [21,32].

Because the worldwide mortality and morbidity of atherosclerosis-related diseases is increasing, the development of noninvasive monitoring of progression of atherosclerosis has become a very important issue for prevention and early treatment of these diseases. Dysfunction of the vascular endothelium has been shown to be the earliest change in atherosclerosis from clinical observations over three decades [4,33]. It has been proved that FMD is a reliable assessment of the bioavailability of endothelial nitric oxide. Impaired FMD in asymptomatic individuals correlates with cardiovascular risk factors such as hypertension, insulin resistance, diabetes mellitus, elevated serum low-density lipoprotein, smoking, and even sedentary lifestyles. Therefore, FMD was recently recommended as a valid parameter in the noninvasive assessment of subclinical

atherosclerosis in children and adolescents [34]. Although therapeutic targeting on vascular endothelial dysfunction has been proposed as a useful strategy in the treatment of atherosclerosis and related diseases [35-37], long-term evaluation of the therapeutic impact on endothelial function in clinical studies is not easy. In addition, the causes of atherosclerosis such as genetic polymorphism or environmental toxins, diet, and oxidation stress are difficult to assess in human subjects. The use of a physiologically and genetically similar animal model, therefore, can serve this purpose. Several animal models of atherosclerosis are available for intervention studies [38,39], but few reliable, noninvasive methods can be used to assess endothelial function. To overcome this limitation, we developed the aforementioned instrument for reliable and easy assessment in long-term monitoring of endothelial function in animal models. This can offer a deeper understanding of the disease process and guide further pharmacological and interventional treatment strategies against atherosclerosis.

CONCLUSION

We designed a reliable instrument to assess endothelial function in small animals using an infrared pulse detector. Similar to that in human beings, the FMD acquired with our system was shown to be mainly nitric oxide mediated. This instrument can be used for the study of the pathogenesis of atherosclerosis through assessing changes in endothelial function and evaluating the efficacy of therapeutic regimens against atherosclerosis in animal models.

Financial support and sponsorship

We acknowledge Miss Szu-Hsuan Chen for her expert technical assistance in animal study. This work was supported by a grant from the National Science Council, Taiwan (NSC99-2221-E-303-001), and an intramural grant from Buddhist Tzu Chi General Hospital, Hualien, Taiwan (TCRD101-16).

Conflicts of interest

There are no conflicts of interest.

REFERENCES

1. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. *Circulation* 2004;109:III27-32.
2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. *Nature* 1980;288:373-6.
3. Cox RH, Haas KS, Moisey DM, Tulenko TN. Effects of endothelium regeneration on canine coronary artery function. *Am J Physiol* 1989;257:H1681-92.
4. Ludmer PL, Selwyn AP, Shook TL, Wayne RR, Mudge GH, Alexander RW, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. *N Engl J Med* 1986;315:1046-51.
5. Joannides R, Bellien J, Thuilleux C. Clinical methods for the evaluation of endothelial function – A focus on resistance arteries. *Fundam Clin Pharmacol* 2006;20:311-20.
6. Ghiadoni L, Versari D, Giannarelli C, Fatta F, Taddei S. Non-invasive diagnostic tools for investigating endothelial dysfunction. *Curr Pharm Des* 2008;14:3715-22.
7. Vallance P, Chan N. Endothelial function and nitric oxide: Clinical relevance. *Heart* 2001;85:342-50.
8. Deanfield JE, Halcox JP, Rabelink TJ. Endothelial function and

- dysfunction: Testing and clinical relevance. *Circulation* 2007;115:1285-95.
9. Yeboah J, Sutton-Tyrrell K, Mcburnie MA, Burke GL, Herrington DM, Crouse JR, et al. Association between brachial artery reactivity and cardiovascular disease status in an elderly cohort: The cardiovascular health study. *Atherosclerosis* 2008;197:768-76.
 10. Stenborg A, Kalimo H, Viitanen M, Terent A, Lind L. Impaired endothelial function of forearm resistance arteries in CADASIL patients. *Stroke* 2007;38:2692-7.
 11. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. *J Hypertens* 2005;23:233-46.
 12. Cohn JN, Quyyumi AA, Hollenberg NK, Jamerson KA. Surrogate markers for cardiovascular disease: Functional markers. *Circulation* 2004;109:IV31-46.
 13. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. *Arterioscler Thromb Vasc Biol* 2003;23:168-75.
 14. Chen PL, Wang PY, Sheu WH, Chen YT, Ho YP, Hu HH, et al. Changes of brachial flow-mediated vasodilation in different ischemic stroke subtypes. *Neurology* 2006;67:1056-8.
 15. Widlansky ME, Gokce N, Keaney JF Jr., Vita JA. The clinical implications of endothelial dysfunction. *J Am Coll Cardiol* 2003;42:1149-60.
 16. Davis CR, Bryan J, Hodgson JM, Woodman R, Murphy KJ. A Mediterranean diet reduces F2-isoprostanes and triglycerides among older Australian men and women after 6 months. *J Nutr* 2017;147:1348-55.
 17. Alqurashi RM, Galante LA, Rowland IR, Spencer JP, Commane DM. Consumption of a flavonoid-rich açai meal is associated with acute improvements in vascular function and a reduction in total oxidative status in healthy overweight men. *Am J Clin Nutr* 2016;104:1227-35.
 18. de Queiroz DB, Ramos-Alves FE, Santos-Rocha J, Duarte GP, Xavier FE. Losartan reverses COX-2-dependent vascular dysfunction in offspring of hyperglycaemic rats. *Life Sci* 2017;184:71-80.
 19. Marchesi C, Ebrahimiyan T, Angulo O, Paradis P, Schiffrin EL. Endothelial nitric oxide synthase uncoupling and perivascular adipose oxidative stress and inflammation contribute to vascular dysfunction in a rodent model of metabolic syndrome. *Hypertension* 2009;54:1384-92.
 20. Chen Q, Sievers RE, Varga M, Kharait S, Haddad DJ, Patton AK, et al. Pharmacological inhibition of S-nitrosoglutathione reductase improves endothelial vasodilatory function in rats *in vivo*. *J Appl Physiol* (1985) 2013;114:752-60.
 21. Heiss C, Sievers RE, Amabile N, Momma TY, Chen Q, Natarajan S, et al. *In vivo* measurement of flow-mediated vasodilation in living rats using high-resolution ultrasound. *Am J Physiol Heart Circ Physiol* 2008;294:H1086-93.
 22. Schuler D, Sansone R, Freudenberger T, Rodriguez-Mateos A, Weber G, Momma TY, et al. Measurement of endothelium-dependent vasodilation in mice – Brief report. *Arterioscler Thromb Vasc Biol* 2014;34:2651-7.
 23. Wu HT, Liu CC, Sun CK, Liu AB, Chen CS, Yang CC, et al. Simultaneous assessment of autonomic nervous and vascular endothelial functions in a rat model. *Biomed Tech (Berl)* 2013;58:205-12.
 24. Kochi T, Imai Y, Takeda A, Watanabe Y, Mori S, Tachi M, et al. Characterization of the arterial anatomy of the murine hindlimb: Functional role in the design and understanding of ischemia models. *PLoS One* 2013;8:e84047.
 25. Kuvin JT, Patel AR, Sliney KA, Pandian NG, Sheffy J, Schnall RP, et al. Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude. *Am Heart J* 2003;146:168-74.
 26. Rahmouni K, Jalali A, Morgan DA, Haynes WG. Lack of dilator effect of leptin in the hindlimb vascular bed of conscious rats. *Eur J Pharmacol* 2005;518:175-81.
 27. Allen J. Photoplethysmography and its application in clinical physiological measurement. *Physiol Meas* 2007;28:R1-39.
 28. Liu AB, Hsu PC, Chen ZL, Wu HT. Measuring pulse wave velocity using ECG and photoplethysmography. *J Med Syst* 2011;35:771-7.
 29. Tsai WC, Chen JY, Wang MC, Wu HT, Chi CK, Chen YK, et al. Association of risk factors with increased pulse wave velocity detected by a novel method using dual-channel photoplethysmography. *Am J Hypertens* 2005;18:1118-22.
 30. Joannides R, Haefeli WE, Linder L, Richard V, Bakkali EH, Thuillez C, et al. Nitric oxide is responsible for flow-dependent dilatation of human peripheral conduit arteries *in vivo*. *Circulation* 1995;91:1314-9.
 31. Hamburg NM, Keyes MJ, Larson MG, Vasan RS, Schnabel R, Pryde MM, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham heart study. *Circulation* 2008;117:2467-74.
 32. Nohria A, Gerhard-Herman M, Creager MA, Hurley S, Mitra D, Ganz P, et al. Role of nitric oxide in the regulation of digital pulse volume amplitude in humans. *J Appl Physiol* (1985) 2006;101:545-8.
 33. Panza JA, Quyyumi AA, Brush JE Jr., Epstein SE. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. *N Engl J Med* 1990;323:22-7.
 34. Urbina EM, Williams RV, Alpert BS, Collins RT, Daniels SR, Hayman L, et al. Noninvasive assessment of subclinical atherosclerosis in children and adolescents: Recommendations for standard assessment for clinical research: A scientific statement from the American Heart Association. *Hypertension* 2009;54:919-50.
 35. Pizzi C, Mancini S, Angeloni L, Fontana F, Manzoli L, Costa GM. Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. *Clin Pharmacol Ther* 2009;86:527-32.
 36. Siasos G, Tousoulis D, Vlachopoulos C, Antoniadis C, Stefanadi E, Ioakeimidis N, et al. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. *Am J Hypertens* 2009;22:586-92.
 37. Schroeter H, Heiss C, Balzer J, Kleinbongard P, Keen CL, Hollenberg NK, et al. (-)-epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans. *Proc Natl Acad Sci U S A* 2006;103:1024-9.
 38. Wang Z, Zou J, Cao K, Hsieh TC, Huang Y, Wu JM, et al. Deacetylated red wine containing known amounts of resveratrol suppresses atherosclerosis in hypercholesterolemic rabbits without affecting plasma lipid levels. *Int J Mol Med* 2005;16:533-40.
 39. Matsumoto M, Sata M, Fukuda D, Tanaka K, Soma M, Hirata Y, et al. Orally administered eicosapentaenoic acid reduces and stabilizes atherosclerotic lesions in ApoE-deficient mice. *Atherosclerosis* 2008;197:524-33.